<DOC>
	<DOCNO>NCT00864071</DOCNO>
	<brief_summary>To compare rate extent absorption griseofulvin test formulation Griseofulvin 125 mg/5 mL Suspension versus reference Grifulvin V® 125 mg/5 mL Suspension fasting condition .</brief_summary>
	<brief_title>A Relative Bioavailability Study Griseofulvin 125 mg/5 mL Suspension Under Fasting Conditions</brief_title>
	<detailed_description>Study Type : Interventional Study Design : A randomized , two-way crossover , open-label , single-dose , fasting design . Official Title : A TWO-WAY CROSSOVER , OPEN-LABEL , SINGLE-DOSE , FED , BIOEQUIVALENCE STUDY OF GRISEOFULVIN 125 mg/5 mL SUSPENSION VERSUS GRIFULVIN V® 125 mg/5 mL SUSPENSION IN NORMAL , HEALTHY , NON-SMOKING MALE AND FEMALE SUBJECTS Further study detail provide Actavis Elizabeth LLC : Primary Outcome Measures : Rate Extend Absorption</detailed_description>
	<mesh_term>Griseofulvin</mesh_term>
	<criteria>1 . Nonsmoking male female minimum age 18 year . 2 . Body Mass Index ( BMI = weight/height2 ) great equal 18.5 kg/m2 less equal 29.9 kg/m2 . 3 . Normal finding physical examination , 12lead ECG vital sign ( blood pressure 100140/6090 mmHg , heart rate 5099 beats/minute , temperature 35.8°C 37SC ) . 4 . Negative drug abuse nicotine . 5 . Negative hepatitis Bsurface antigen , hepatitis C HIV . 6 . Female subject : negative pregnancy ( evaluate serum βCG test ) . 7 . No clinical laboratory value outside acceptable range define BCR , unless Principal Investigator decide clinically significant . 8 . Female subject surgically sterile least 6 month postmenopausal least 1 year , avoid pregnancy least 10 day study , study 1 month end study . 9 . Availability subject entire study period willingness subject adhere protocol requirement , evidence sign ICF . 1 . Known history hypersensitivity griseofulvin ( e.g . Grifulvin V® , grisPEG® , Fulvicin® ) penicillin , drug derive specie Penicillium . 2 . Known history presence cardiac , pulmonary , gastrointestinal , endocrine , musculoskeletal , neurological , hematological , liver kidney disease , unless deem clinically significant Principal Investigator Subinvestigator . 3 . Presence significant physical organ abnormality . 4 . Any history evidence psychiatric psychological disease ( include depression ) unless deem clinically significant Principal Investigator Subinvestigator . 5 . History presence skin condition ( e.g . dermatitis , eczema , psoriasis ) . 6 . Presence skin rash . 7 . Any subject previously diagnose porphyria . 8 . Any clinically significant illness 4 week study . 9 . Any subject treat known enzymealtering drug barbiturate , phenothiazine , cimetidine , carbamazepine , etc. , within 30 day prior first dose study medication . 10 . Known history presence food allergy , condition know interfere absorption , distribution , metabolism excretion drug . 11 . Any history severe allergic reaction ( include drug , food , insect bite , environmental allergen ) . 12 . Significant recent history asthma ( 12 year age ) . 13 . Any subject history drug abuse . 14 . Any subject recent ( less 1 year ) history alcohol abuse . 15 . Use prescription medication within 14 day precede study . 16 . Use overthecounter ( OTC ) medication within 7 day precede study ( except spermicidal/barrier contraceptive product ) . 17 . Female subject : use contraceptive ( oral , emergency [ Plan B® ] , transdermal , implant , Mirena® IUD , NuvaRing® ) within 30 day drug administration depot injection progestogen drug ( e.g . DepoProvera® ) within 1 year drug administration . 18 . Female subject : evidence pregnancy lactation . 19 . Any subject blood drawn within 56 day precede study , conduct clinical study facility BCR , within lockout period specify previous study conduct BCR . 20 . Participation clinical trial investigational drug within 30 day precede study . 21 . Any subject donate blood within 56 day precede study . 22 . Any subject participate plasma donor plasmapheresis program within 7 day precede study . 23 . Any subject adhere significantly abnormal diet 4 week precede first dose study . 24 . Intolerance venipuncture .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Griseofulvin</keyword>
	<keyword>Healthy subject</keyword>
</DOC>